Acer Competitors

Delisted . USA . 
Stock . Acer Therapeutics
ACERDelisted Stock  USD 0.84  0.02  2.33%   
Acer Therapeutics competes with Pasithea Therapeutics, SAB Biotherapeutics, Lexaria Bioscience, ZyVersa Therapeutics, and Biodexa Pharmaceticals; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing Acer Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Acer Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Acer Therapeutics competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Acer Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.840.840.84
Details
Intrinsic
Valuation
LowRealHigh
0.730.730.92
Details
Naive
Forecast
LowNextHigh
0.830.830.83
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.780.880.98
Details

Acer Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Acer Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Acer and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Acer Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
ZVSA
+ 0.86
KTTA
LEXX
+ 0.82
KTTA
KRBP
+ 0.82
LEXX
ZVSA
+ 0.8
LEXX
NAVB
+ 0.77
LEXX
ONCR
+ 0.75
ZVSA
  
High negative correlations   
LEXX
- 0.62
SABS
SABS
- 0.61
KTTA
KRBP
- 0.58
SABS
ZVSA
- 0.53
SABS
LEXX
- 0.46
RLFFD
ONCR
- 0.45
SABS

Risk-Adjusted Indicators

There is a big difference between Acer Stock performing well and Acer Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Acer Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
RLFFD  1,698  865.95  142.81  9.14  0.00 
(3,326)
 7.77 
(11.19)
 36,552 
NRXPW  9.79  0.41  0.02 (0.09) 13.83 
(10.43)
 24.50 
(28.29)
 62.80 
KTTA  4.85 (0.58) 0.00 (1.18) 0.00 
 0.00 
 7.39 
(11.00)
 68.44 
SABS  6.69  1.07  0.15  1.22  6.77 
(7.95)
 19.02 
(11.50)
 65.66 
LEXX  3.06 (0.49) 0.00 (8.23) 0.00 
 0.00 
 5.94 
(6.19)
 30.19 
NAVB  6.04 (1.09) 0.00  1.61  0.00 
 0.00 
 12.50 
(12.50)
 40.40 
ZVSA  3.88 (0.61) 0.00  0.21  0.00 
 0.00 
 10.00 
(7.14)
 78.93 
BDRX  6.62 (0.73) 0.00 (0.29) 0.00 
 0.00 
 13.30 
(19.70)
 97.78 
ONCR  8.13 (2.20) 0.00 (0.75) 0.00 
 0.00 
 10.00 
(21.20)
 120.67 
KRBP  6.00 (0.26) 0.00 (0.04) 0.00 
 0.00 
 12.04 
(10.96)
 65.24 
All Fundamental Data

Acer Therapeutics Competitive Analysis

The better you understand Acer Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Acer Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Acer Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ACER RLFFD NRXPW KTTA SABS LEXX NAVB ZVSA BDRX ONCR
 2.33 
 0.84 
Acer
 4.33 
 3.13 
Relief
 24.06 
 0.06 
NRx
 5.12 
 2.67 
Pasithea
 7.44 
 4.19 
SAB
 1.36 
 2.18 
Lexaria
 9.45 
 0.1 
Navidea
 12.73 
 1.24 
ZyVersa
 1.78 
 4.00 
Biodexa
 14.71 
 0.04 
Oncorus
Market Volatility
(90 Days Market Risk)
Very steady
Unknown risk
Out of control
Dangerous
Dangerous
Risky
Very steady
Extremely Dangerous
Dangerous
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Insignificant
Very Weak
Modest
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Unknown
High
Low
Average
About Average
Dangerous
About Average
Very High
Dangerous
Current Valuation
(Equity Enterprise Value)
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Under Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Strong Buy
Strong Buy
Buy
Not Available
Strong Buy
Strong Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Not Rated
Strong Sell
Cautious Hold
Hold
Strong Sell
Not Rated
Strong Sell
Strong Sell
Not Rated
Current Ratio
0.87
4.58
51.17
1.72
40.09
0.22
N/A
N/A
6.42
Net Asset
11.62 M
7.32 M
26.12 M
83.94 M
8.87 M
4.37 M
22.11 M
10.54 M
145.59 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(24.81 M)
(30.02 M)
(15.33 M)
(38.08 M)
(5.75 M)
(14.05 M)
(107.74 M)
(7.16 M)
(75.42 M)
Current Valuation
52.01 M
N/A
(8.77 M)
5.13 M
30.41 M
3.5 M
(528.61 K)
(3.66 M)
25.71 M
Price To Book
17.26
N/A
0.18
0.84
4.58
8.16
0.37
0.21
0.13
Operating Margin
N/A
N/A
N/A
-34.23
-20.75
N/A
N/A
-79.31
N/A
Retained Earnings
(140.75 M)
(253.15 M)
(35.32 M)
(90.06 M)
(51.56 M)
(388 M)
(103.22 M)
(144.77 M)
(272.01 M)
Current Asset
6.61 M
N/A
N/A
N/A
N/A
12.58 M
N/A
N/A
N/A
Beta
0.44
1.27
0.82
0.64
1.06
1.5
0.64
1.44
2.85
Number Of Employees
30
N/A
8
57
5
11
7
21
64
Shares Outstanding
24.46 M
N/A
1.27 M
9.23 M
17.45 M
100.08 M
2.34 M
580.84 K
26.09 M
Cash Flow From Operations
(30.25 M)
(21.66 M)
(13.43 K)
(25.12 M)
(4.96 M)
(8.99 M)
(8.72 M)
(6.83 M)
(61.69 M)
Annual Yield
0.035
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
11.86 M
9.16 M
81.68 K
5.91 M
137.37 K
2.43 M
8.66 K
464 K
70.65 M
Return On Equity
-4.73
-6.83
-0.63
-1.75
-0.71
-11.0
-1.52
-0.97
-1.25
Z Score
-24.48
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-4.07
Return On Asset
-0.65
-1.16
-0.38
-0.79
-0.38
-1.22
-0.25
-0.38
-0.32
Number Of Shares Shorted
493.55 K
3.94 K
24.2 K
98.95 K
298.17 K
2.69 M
38.96 K
51.99 K
447.72 K
Book Value Per Share
-1.36
-1.42
22.46
4.0
0.64
-0.011
27.33
24.07
1.19
Current Liabilities
5.62 M
N/A
N/A
N/A
N/A
6.18 M
N/A
N/A
N/A
Total Asset
11.62 M
7.32 M
26.12 M
83.94 M
8.87 M
4.37 M
22.11 M
10.54 M
145.59 M
Debt To Equity
0.081
0.016
0.008
0.16
0.007
1.2
N/A
N/A
0.72
Short Ratio
2.87
N/A
0.32
1.22
2.34
0.52
0.19
0.17
0.74
Target Price
1.5
N/A
2.0
12.4
10.0
5.0
20.0
197.78
5.0
Shares Owned By Institutions
29.91
N/A
2.86
34.24
6.0
1.5
4.47
35.25
55.29
Market Capitalization
22.02 M
714.61 M
3.22 M
30.83 M
36.82 M
8.04 M
2.58 M
2.28 M
3.15 M
Price To Earning
-7.4
N/A
N/A
N/A
N/A
0.53
N/A
N/A
N/A
Price To Sales
174.52
N/A
42.15
20.38
89.59
84.14
N/A
27.5
N/A
Net Income
(26.24 M)
(30.15 M)
(15.51 M)
(42.19 M)
(5.81 M)
(15.18 M)
(98.3 M)
(7.08 M)
(77.42 M)
Earnings Per Share
-1.98
-6.25
-14.79
-6.3
-0.47
-0.39
491.97
-76.26
-5.49
Shares Owned By Insiders
13.78
N/A
23.12
19.15
7.0
35.43
0.61
10.16
12.69
Revenue
N/A
N/A
486.56 K
2.24 M
464.28 K
65.65 K
N/A
381 K
N/A
Working Capital
(15.44 M)
(12.16 M)
14.06 M
48.09 M
1.93 M
(6.74 M)
(6.84 M)
1.46 M
27.41 M
Cash And Equivalents
14.47 M
24.55 M
47.94 M
16.62 M
7.34 M
328.01 K
N/A
N/A
100.24 M
Cash Per Share
0.91
0.36
1.8
0.39
1.23
0.01
N/A
N/A
3.86
Gross Profit
1.26 M
N/A
(2.21 K)
(12.53 M)
183.56 K
(119.3 K)
N/A
(4.41 M)
N/A
Day Typical Price
0.84
3.09
0.0668
2.62
4.09
2.18
0.1
1.19
3.98
0.0472
Accumulation Distribution
0.0349
0.0415
0.25
0.0562
0.0692
N/A
0.11
0.11
0.0175
0.37
Market Facilitation Index
0.03
0.13
0.0197
0.15
0.29
N/A
0.012
0.14
0.07
0.022
Daily Balance Of Power
(0.67)
1.0
(0.97)
0.8667
1.0
(9,223,372,036,855)
(0.87)
1.0
1.0
(0.34)
Period Momentum Indicator
(0.02)
0.13
(0.02)
0.13
0.29
(0.03)
(0.01)
0.14
0.07
(0.01)
Rate Of Daily Change
0.98
1.04
0.76
1.05
1.07
0.99
0.91
1.13
1.02
0.85
Day Median Price
0.85
3.07
0.0699
2.6
4.05
2.18
0.1
1.17
3.97
0.049
Price Action Indicator
(0.01)
0.13
(0.02)
0.14
0.29
(0.01)
(0.01)
0.14
0.07
(0.01)
Coefficient Of Variation
(2,077)
649.39
4070.15
(1,602)
925.3
(905.43)
(762.99)
(1,184)
(1,775)
(655.56)
Mean Deviation
3.35
1698.48
9.79
4.85
6.69
3.06
6.04
3.88
6.62
8.13
Jensen Alpha
(0.21)
865.95
0.4117
(0.58)
1.07
(0.49)
(1.09)
(0.61)
(0.73)
(2.20)
Total Risk Alpha
(0.37)
701.88
(0.08)
(0.83)
0.7896
(0.62)
(1.35)
(0.93)
(1.02)
(2.54)
Sortino Ratio
N/A
142.81
0.0176
N/A
0.1468
N/A
N/A
N/A
N/A
N/A
Downside Variance
N/A
36.96
301.05
N/A
52.74
N/A
N/A
N/A
N/A
N/A
Standard Deviation
4.58
5637.96
13.8
8.94
10.18
4.34
8.36
8.05
11.78
13.92
Kurtosis
0.8583
42.0
0.566
18.8
7.08
7.46
0.7251
16.91
17.43
11.31
Potential Upside
8.33
7.77
24.5
7.39
19.02
5.94
12.5
10.0
13.3
10.0
Treynor Ratio
0.2756
9.14
(0.09)
(1.18)
1.22
(8.23)
1.61
0.2101
(0.29)
(0.75)
Maximum Drawdown
21.89
36551.86
62.8
68.44
65.66
30.19
40.4
78.93
97.78
120.67
Variance
21.0
3.17865803E7
190.54
79.91
103.57
18.84
69.93
64.78
138.71
193.82
Market Risk Adjusted Performance
0.2856
9.15
(0.08)
(1.17)
1.23
(8.22)
1.62
0.2201
(0.28)
(0.74)
Risk Adjusted Performance
(0.03)
0.1323
0.0289
(0.04)
0.095
(0.08)
(0.1)
(0.06)
(0.04)
(0.11)
Skewness
0.4896
6.48
(0.17)
3.35
1.88
1.79
0.2409
0.4045
2.62
0.7357
Semi Deviation
N/A
0.0
13.83
N/A
6.77
N/A
N/A
N/A
N/A
N/A
Information Ratio
(0.06)
0.154
0.0221
(0.07)
0.1048
(0.12)
(0.14)
(0.09)
(0.06)
(0.15)
Value At Risk
(7.37)
(11.19)
(28.29)
(11.00)
(11.50)
(6.19)
(12.50)
(7.14)
(19.70)
(21.20)
Expected Short fall
N/A
(3,326)
(10.43)
N/A
(7.95)
N/A
N/A
N/A
N/A
N/A
Downside Deviation
N/A
6.08
17.35
N/A
7.26
N/A
N/A
N/A
N/A
N/A
Semi Variance
N/A
(853.82)
191.23
N/A
45.79
N/A
N/A
N/A
N/A
N/A

Acer Therapeutics Competition Performance Charts

Five steps to successful analysis of Acer Therapeutics Competition

Acer Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Acer Therapeutics in relation to its competition. Acer Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Acer Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Acer Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Acer Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Acer Therapeutics position

In addition to having Acer Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Disruptive Technologies Thematic Idea Now

Disruptive Technologies
Disruptive Technologies Theme
New or established technology companies and funds across multiple sectors that are involved in development or marketing of products or services that experience disruptive trends and that are at the forefront of discussions on Wall Street. The Disruptive Technologies theme has 64 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Disruptive Technologies Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Other Consideration for investing in Acer Stock

If you are still planning to invest in Acer Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acer Therapeutics' history and understand the potential risks before investing.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Stocks Directory
Find actively traded stocks across global markets
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY